Advertisement


Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

IASLC 2020 World Conference on Lung Cancer in Singapore

Advertisement

Fred R. Hirsch, MD, PhD, of Mount Sinai Medical Center, discusses Lung-MAP studies in which a higher tumor mutation burden determined by next-generation sequencing was linked to overall and progression-free survival across two immunotherapy trials, and was independent of PD-L1 status (Abstract OA01.04).



Related Videos

Solid Tumors
Immunotherapy

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success fo...

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Martin Reck, MD, PhD, of the LungenClinic, discusses findings of the KEYNOTE-598 study, which showed that pembrolizumab plus ipilimumab was more toxic and offered no more ben...

Lung Cancer

Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer

Jill Feldman, a patient advocate who has lost five family members to lung cancer and is herself a 12-year cancer survivor living with EGFR-positive disease, describe...

Lung Cancer
Immunotherapy

Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab

Justin F. Gainor, MD, of Massachusetts General Hospital, discusses two key phase II studies on non–small cell lung cancer: nivolumab vs nivolumab plus ipilimumab in EGFR<...

Lung Cancer

Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

Silvia Novello, MD, PhD, of the University of Turin, disc...

Advertisement

Advertisement



Advertisement